EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Validation of Proposed Criteria for Progressive Pulmonary Fibrosis

Janelle Vu Pugashetti iD, Ayodeji Adegunsoye, Zhe Wu, Cathryn T Lee, Anand Srikrishnan, Sahand Ghodrati, Vivian Vo, Elisabetta A Renzoni, Athol U Wells, Christine Kim Garcia iD, Felix Chua, Chad A Newton und 2 weitere

American Journal of Respiratory and Critical Care Medicine · 01.01.2023 · 207 (1) · 69-76

DOI: 10.1164/rccm.202201-0124oc ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Respiratory and Critical Care Medicine, online erschienen am 01.01.2023. Verfasst von Janelle Vu Pugashetti und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis, Connective Tissue Diseases. Die Arbeit wurde bisher 145-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Versus Arthritis, NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Criteria for progressive pulmonary fibrosis (PPF) have been proposed, but their prognostic value beyond categorical decline in FVC remains unclear.

Objectives

To determine whether proposed PPF criteria predict transplant-free survival (TFS) in patients with non–idiopathic pulmonary fibrosis (IPF) forms of interstitial lung disease (ILD).

Methods

A retrospective, multicenter cohort analysis was performed. Patients with diagnoses of fibrotic connective tissue disease–associated ILD, fibrotic hypersensitivity pneumonitis, and non-IPF idiopathic interstitial pneumonia from three U.S. centers and one UK center constituted the test and validation cohorts, respectively. Cox proportional hazards regression was used to test the association between 5-year TFS and ≥10% FVC decline, followed by 13 additional PPF criteria satisfied in the absence of ≥10% FVC decline. Measurements and Main Results One thousand three hundred forty-one patients met the inclusion criteria. A ≥10% relative FVC decline was the strongest predictor of reduced TFS and showed consistent TFS association across cohorts, ILD subtypes, and treatment groups, resulting in a phenotype that closely resembled IPF. Ten additional PPF criteria satisfied in the absence of 10% relative FVC decline were also associated with reduced TFS in the U.S. test cohort, with 6 maintaining TFS associations in the UK validation cohort. Validated PPF criteria requiring a combination of physiologic, radiologic, and symptomatic worsening performed similarly to their stand-alone components but captured a smaller number of patients.

Conclusions

An FVC decline of ≥10% and six additional PPF criteria satisfied in the absence of such decline identify patients with non-IPF ILD at increased risk for death or lung transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialIdiopathic Pulmonary FibrosisConnective Tissue DiseasesHumansRetrospective StudiesPrognosisDisease Progression

Stichwörter der Autor:innen

idiopathic interstitial pneumoniaidiopathic pulmonary fibrosisinterstitial lung diseaseprogressive fibrosing interstitial lung diseaseprogressive pulmonary fibrosis

Autor:innen und Institutionen

  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
  • Division of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis, Davis, California.
  • Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois.
  • National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.
  • Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; and.

ORCID-Profile: Janelle Vu Pugashetti, Christine Kim Garcia, Justin M Oldham

Förderung

  • NHLBI NIH HHS
  • Versus Arthritis
  • NIEHS NIH HHS
  • NCATS NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Pugashetti, J. V., Adegunsoye, A., Wu, Z., Lee, C. T., Srikrishnan, A., Ghodrati, S., Vo, V., Renzoni, E. A., Wells, A. U., Garcia, C. K., Chua, F., Newton, C. A., Molyneaux, P. L., & Oldham, J. M. (2023). Validation of Proposed Criteria for Progressive Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 207(1), 69-76. https://doi.org/10.1164/rccm.202201-0124oc

Vancouver

Pugashetti JV, Adegunsoye A, Wu Z, Lee CT, Srikrishnan A, Ghodrati S, et al. Validation of Proposed Criteria for Progressive Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2023;207(1):69-76. doi:10.1164/rccm.202201-0124oc

BibTeX
@article{Pugashetti2023,
  author = {Pugashetti, Janelle Vu and Adegunsoye, Ayodeji and Wu, Zhe and Lee, Cathryn T and Srikrishnan, Anand and Ghodrati, Sahand and Vo, Vivian and Renzoni, Elisabetta A and Wells, Athol U and Garcia, Christine Kim and Chua, Felix and Newton, Chad A and Molyneaux, Philip L and Oldham, Justin M},
  title = {Validation of Proposed Criteria for Progressive Pulmonary Fibrosis},
  journal = {American Journal of Respiratory and Critical Care Medicine},
  year = {2023},
  volume = {207},
  number = {1},
  pages = {69--76},
  doi = {10.1164/rccm.202201-0124oc}
}
Kostenlos starten →